Oncolytic VACVs expressing PD-L1 inhibitors and GM-CSF activated tumor neoantigen-specific T-cell responses by synergistic action of VACV replication, GM-CSF stimulation, and PD-L1 inhibition on tumor cells and immune cells (93). Here, CD274 is linked to neoplasm.